Pieris Ag

Basf Se Corporation

Pieris Pharmaceuticals Gmbh

Pieris Proteolab Ag

Steffen Schlehuber

Arne Skerra

Andreas Hohlbaum

Kristian Hobolt Jensen

Martin Huelsmeyer

Eric Boudreau

Richard Jones

Ian Kimber

Rebecca Dearman

Gabriele Matschiner

Claude Taranta

Sarah Thompson

Wolfgang Meier

Paulo Cesar Queiroz

Jochen Schreieck

Helmut Mueller

Helmut Müller

Martin Pöhlchen

Richard C Jones

The present invention relates to an aqueous pesticide microemulsion formulation including (a) at least one organic pesticide compound P, which is sparingly soluble in water and which is present in the formulation in dissolved form; (b) at least one organic solvent LM1 selected from C1-C4-alkyl lactates; (c) at least one organic solvent LM2 selected from C5-C12-alkyl lactates; (d) at least one organic solvent LM3 selected from N&#x2014;(C4-C12 alkyl)pyrrolidones; (e) at least one surfactant S selected from anionic surfactants and non-ionic surfactants and mixtures thereof; and (f) water.

Aqueous pesticide microemulsion

The present invention relates to novel muteins derived from human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.

Muteins of tear lipocalin and methods for obtaining the same

The present invention relates to a compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4), wherein the compound exhibits a synergistic mode of action in that the compound: (a) increases T cell priming or T cell expansion or the generation of memory T cells by blocking of CTLA-4, and (b) enhances effector T cell activity in tumor tissue or lymphoid tissue by blocking of CTLA-4. The compound of the invention can be a protein, a small organic molecule, a peptide, or a nucleic acid. The invention also relates to a mutein derived from a protein selected from the group consisting of human neutrophil gelatinase-associated lipocalin (hNGAL), rat &#x3b1;2-microglobulin-related protein (A2m) and mouse 24p3/uterocalin (24p3), said mutein having binding specificity for the cytotoxic T lymphocyte-associated antigen (CTLA-4), wherein said mutein: (a) comprises amino acid replacements at least one of the sequence position corresponding to sequence positions 33 to 54, 66 to 83, 94 to 106, and 123 to 136 of hNGAL, and (b) binds human CTLA-4 with a Kof 50 nM or less. The invention also relates to a pharmaceutical composition comprising such a compound or mutein as well as to various pharmaceutical uses of such a compound or mutein, for example, for the prevention and/or treatment of cancer, an auto-immune disease or an infectious disease.

Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)

The present invention relates to novel muteins derived from tear lipocalin or a homologue thereof. In particular, the invention relates to a mutein of human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various use of the mutein.

Muteins of human tear lipocalin

The present invention relates to novel muteins derived from a bilin-binding protein (BBP) that binds a given target, for example a macromolecular target, with detectable affinity. In particular, the invention relates to a mutein of the bilin-binding protein of. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various use of the mutein.

Muteins of a bilin-binding protein with affinity for a given target

Disclosed is a method for generating a mutein of a protein selected from the group consisting of human neutrophil gelatinase-associated lipocalin (hNGAL), rat &#x3b1;-microglobulin-related protein (A2m) and mouse 24p3/uterocalin (24p3), said mutein having detectable affinity to a given target. The method comprises the step of subjecting the protein to mutagenesis at one or more of the sequence positions which correspond to the sequence positions 33 to 54, 66 to 83, 94 to 106, and 123 to 136 of hNGAL, resulting in one or more mutein(s) of the protein. Also disclosed are muteins obtainable by this method.

Muteins of human neutrophil gelatinase-associated lipocalin and related proteins

The present invention relates to muteins of the bilin-binding protein with binding activity to digoxigenin and to fusion proteins of such muteins, a method for preparing said muteins and fusion proteins thereof and their utilization for detecting or binding digoxigenin-labeled biomolecules. The invention especially relates to a polypeptide selected from muteins of the bilin-binding protein, characterized in that (a) it can bind digoxigenin or digoxigenin conjugates, (b) it does not bind ouabain, testosterone, and 4-aminofluorescein and (c) at least one of the sequence positions 28, 31, 34, 35, 36, 37, 58, 60, 69, 88, 90, 95, 97, 114, 116, 125, and 127 of the bilin-binding protein has an amino acid substitution. Due to their simple molecular structure, the inventive muteins provide advantages for production and utilization in comparison with antibodies against the digoxigenin group.

Muteins of bilin-binding protein

Growing community of inventors

Langenbach, Germany

Steffen Schlehuber